PepMix™ Peptide Pools

The use of mixtures of pooled overlapping peptides (e.g. for a certain virus or tumor antigen such as CMV pp65 or erbB2) or mixed antigenic peptides (e.g. CEF Pools with antigens from CMV, EBV and Influenza) is extremely efficient for immunostimulation of T-cells.  JPT Peptide Technologies  offers a huge and still growing number of cost-effective and ready-to-use PepMix™ Peptide Pools and PepMix™ Peptide Pool Collections. Alternatively, we prepare your customized peptide pool fast and economically according to your specific needs or provide the respective individual peptides.

Control Peptide Pools for T-cell Assays

error fetching data, please contact support

PepMix™ Collections for Immune Response Qualification

error fetching data, please contact support

Peptide Pools for Infectious Diseases Antigens

error fetching data, please contact support

Peptide Pools for Tumor Associated Antigens

error fetching data, please contact support

Tailored PepMixes™ & Matrix Peptide Pools

Custom PepMixes™ Peptide Pools

You need a specific antigen or specialized peptide pool layout?
We are happy to discuss your specifications and provide your tailored PepMixes™ or matrix pool. Our customer support team will assist with sequence and pool design. Subsequently, we will chemically synthesize, purify and analyze the peptides to comply with the requirements of T-cell assays. All peptide synthesis steps are optimized to avoid contaminations and failure sequences which may lead to false positive T-cell responses or inhibition of T-cell responses.
Pooling and aliquotation will be performed using our validated protocol that ensures presence of all peptides in the respective pools. Our fully automated aliquotation service yields freeze dried pool aliquots avoiding deterioration of peptides.

Custom PepMix Production

Production of Customized PepMix Peptide Pools

Individual Peptides

In addition to tailored and off-the-shelf PepMix™ Peptide Pools, we are happy to provide the individual peptides to validate results or for further experiments.  As for the PepMix™ Peptide Pools, each individual peptide is quality controlled to ensure batch-to-batch reproducibility!
Our peptide synthesis, purification as well as aliquotation and pooling are controlled by our ISO certified quality management system.

Please inquire via email!

Applications for PepMix™ Peptide Pools

  • Antigen specific immunostimulation of T-lymphocytes
  • Monitoring of immune status during diseases or therapy
  • Assessment of vaccine efficacy
  • T-cell expansion
  • Cellular immune response profiling
  • Identification of the best antigen for individual patients (PepMix™ Collections)

    Application Notes:

    Download our Application Note on CMV PepMixes™:
    "Cytomegalovirus protein spanning PepMix™ peptide pools to discover changes in T cell immunity in the aging population"
    by F. Kern, Brighton and Sussex Medical School, UK

    Download our Application Note on PepMixes™ Peptide Pools for Clinical Applications:
    "T cell therapy for viral infections after hematopoietic stem cell transplant"
    by A. M. Leen, Baylor College of Medicine TX, USA

    Download our Application Note on Peptide library and pool qualification for clinical trials:
    "Qualification and use of peptide libraries for clinical trial immunomonitoring"
    by Josephine H Cox & Peter Hayes, The International AIDS Vaccine Initiative, London, GB

Benefits of PepMix™ Peptide Pools

Peptide pools are preferable to whole proteins for T cell stimulation because:

  • Equivalent or better stimulation of CD4 and CD8 cells with peptides
  • More reliable as control than phytohemagglutinin (PHA) and concanavalin A (ConA)
  • Improved responses in stored blood and PBM cells with peptides
  • High-batch-to-batch reproducibility
  • Reliable chemical and biochemical quality control and quality assurance are applicable for peptide synthesis and peptide pool generation
  • Prolonged shelf stability when stored freeze dried

    Testimonials for PepMix™ Peptide Pools

    "I have used JPT's peptide pools (PepMix™) for years now, with great satisfaction! First CMV derived peptides and now also EBV. So far we have published data in one publication and plan several more in the near future."

    Anna Karin Lidehaell (Uppsala University, Clin. Immunol., Uppsala, Sweden)

    "The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptide synthesis and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
    Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

    More testimonials under JPT Testimonials

    Selected References for PepMix™ Peptide Pools:

    Abstracts available from PubMed:


    Control Pools:
    Statistical Methods for the Assessment of EQAPOL Proficiency Testing: ELISpot, Luminex, and Flow Cytometry
    Rountree et al., J Immunol Methods (2014) - PMID: 24456626
    Polyfunctional T Cells Accumulate in Large Human Cytomegalovirus-Specific T Cell Responses
    Lachmann et al., J. Virol. (2012) - PMID: 22072753
    Generation of a Multipathogen-Specific T-cell Product for Adoptive Immunotherapy Based on Activation-Dependent Expression of CD154
    Khanna et al., Blood (2011) - PMID: 21642594
    AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
    Malmström et al., Clin. Cancer Res. (2010) - PMID: 20448220

    Infectious Diseases:
    A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology
    Terrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779
    Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XII
    Faxälv et al., Blood, (2013) - PMID: 23896408
    Characterization of the T-Cell–Mediated Immune Response Against the Aspergillus fumigatus Proteins Crf1 and Catalase 1 in Healthy Individuals
    Jolink et al., The Journal of Infectious Disease (2013) - PMID: 23698813
    Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
    Blaney et al., PLOS Pathogens (2013) - PMID: 23737747
    Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell Transplantation
    Blyth et al., Blood. (2013) - PMID: 23435462
    An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
    Skoberne et al., J. Virol. (2013) - PMID: 23365421
    Distinct Gene-expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
    Hu et al., Blood. (2013) - PMID: 23258923
    T-cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
    Secondino et al., Ann. Onc. (2012) - PMID: 21586688

    Tumor Associated Antigens:
    Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
    Gerdemann et al., Molecular Therapy (2011) - PMID: 21915103
    Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
    Cruz et al., Clin. Cancer Res. (2011) - PMID: 21908573
    Prophylactic Transfer of BCR-ABL–, PR1-, and WT1-Reactive Donor T Cells after T cell–Depleted Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Myeloid Leukemia
    Bornhäuser et al., Blood. (2011) - PMID: 21540460

    More references under JPT Publications/Literature

    Peptide tools for cancer research
    Quote Request

    Request a price for
    Catalog PepMixes™
    Request a price for
    Tailored PepMixes™
    Order directly

    News on PepMix™

    Check our brand-new PepMixes™ related to a variety of infections and
    tumor associated antigens, e.g.:
    Human (PAP)
    EBV (BARF1)
    and HPV (L1)
    (February 2014)

    --> Read more news

    Contact us!

    Please feel free to call or send us an email to
    +1 978 631 4225 (US/Canada only)

    JPT's Quality Assurance

    All production is performed in JPT's head offices in Berlin, Germany according to ISO 9001:2008 standards